Vertex Pharmaceuticals Incorporated (0QZU.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 06:02PM BST. Market open.
| Previous close | 310.51 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 80.326B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 29.79 |
| EPS (TTM) | 10.49 |
| Earnings date | 03 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $308.47, marking a -1.88% move from the previous day.
- Simply Wall St.
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock Has Fared Decently: Is the Market Following Strong Financials?
Vertex Pharmaceuticals' (NASDAQ:VRTX) stock is up by 9.4% over the past three months. Since the market usually pay for...
- Business Wire
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
BOSTON & ZUG, Switzerland, March 27, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D).
© 2023 Yahoo. All rights reserved.
